Literature DB >> 21469091

Reduced IL-2 expression in NOD mice leads to a temporal increase in CD62Llo FoxP3+ CD4+ T cells with limited suppressor activity.

Kevin S Goudy1, Mark C Johnson1, Alaina Garland1, Chengwen Li2, Richard J Samulski2, Bo Wang1, Roland Tisch1,3.   

Abstract

IL-2 plays a critical role in the induction and maintenance of FoxP3-expressing regulatory T cells (FoxP3(+) Tregs). Reduced expression of IL-2 is linked to T-cell-mediated autoimmune diseases such as type 1 diabetes (T1D), in which an imbalance between FoxP3(+) Tregs and pathogenic T effectors exists. We investigated the contribution of IL-2 to dysregulation of FoxP3(+) Tregs by comparing wildtype NOD mice with animals congenic for a C57BL/6-derived disease-resistant Il2 allele and in which T-cell secretion of IL-2 is increased (NOD.B6Idd3). Although NOD mice exhibited a progressive decline in the frequency of CD62L(hi) FoxP3(+) Tregs due to an increase in CD62L(lo) FoxP3(+) Tregs, CD62L(hi) FoxP3(+) Tregs were maintained in the pancreatic lymph nodes and islets of NOD.B6Idd3 mice. Notably, the frequency of proliferating CD62L(hi) FoxP3(+) Tregs was elevated in the islets of NOD.B6Idd3 versus NOD mice. Increasing levels of IL-2 in vivo also resulted in larger numbers of CD62L(hi) FoxP3(+) Tregs in NOD mice. These results demonstrate that IL-2 influences the suppressor activity of the FoxP3(+) Tregs pool by regulating the balance between CD62L(lo) and CD62L(hi) FoxP3(+) Tregs. In NOD mice, reduced IL-2 expression leads to an increase in nonsuppressive CD62L(lo) FoxP3(+) Tregs, which in turn correlates with a pool of CD62L(hi) FoxP3(+) Tregs with limited proliferation.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21469091      PMCID: PMC3805504          DOI: 10.1002/eji.201040890

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  50 in total

1.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

Review 2.  Foxp3 and natural regulatory T cells: key to a cell lineage?

Authors:  Fred Ramsdell
Journal:  Immunity       Date:  2003-08       Impact factor: 31.745

3.  The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.

Authors:  C L Bennett; J Christie; F Ramsdell; M E Brunkow; P J Ferguson; L Whitesell; T E Kelly; F T Saulsbury; P F Chance; H D Ochs
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

4.  Loss of parity between IL-2 and IL-21 in the NOD Idd3 locus.

Authors:  Helen M McGuire; Alexis Vogelzang; Natasha Hill; Malin Flodström-Tullberg; Jonathan Sprent; Cecile King
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-30       Impact factor: 11.205

Review 5.  IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26.

Authors:  P Conti; D Kempuraj; S Frydas; K Kandere; W Boucher; R Letourneau; B Madhappan; K Sagimoto; S Christodoulou; T C Theoharides
Journal:  Immunol Lett       Date:  2003-09-08       Impact factor: 3.685

6.  Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development.

Authors:  Silvia Gregori; Nadia Giarratana; Simona Smiroldo; Luciano Adorini
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

7.  CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2.

Authors:  Thomas R Malek; Aixin Yu; Vladimir Vincek; Paul Scibelli; Lin Kong
Journal:  Immunity       Date:  2002-08       Impact factor: 31.745

8.  The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7.

Authors:  Veronika Szanya; Joerg Ermann; Cariel Taylor; Claire Holness; C Garrison Fathman
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

9.  Interleukin 2 signaling is required for CD4(+) regulatory T cell function.

Authors:  Gláucia C Furtado; Maria A Curotto de Lafaille; Nino Kutchukhidze; Juan J Lafaille
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

10.  Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state.

Authors:  Sylvain Fisson; Guillaume Darrasse-Jèze; Elena Litvinova; Franck Septier; David Klatzmann; Roland Liblau; Benoît L Salomon
Journal:  J Exp Med       Date:  2003-08-25       Impact factor: 14.307

View more
  14 in total

1.  β-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice.

Authors:  Fatima Manzoor; Mark C Johnson; Chengwen Li; R Jude Samulski; Bo Wang; Roland Tisch
Journal:  Eur J Immunol       Date:  2016-11-25       Impact factor: 5.532

2.  IL-1R1 is expressed on both Helios(+) and Helios(-) FoxP3(+) CD4(+) T cells in the rheumatic joint.

Authors:  M Müller; J Herrath; V Malmström
Journal:  Clin Exp Immunol       Date:  2015-07-30       Impact factor: 4.330

3.  Genetic interactions among Idd3, Idd5.1, Idd5.2, and Idd5.3 protective loci in the nonobese diabetic mouse model of type 1 diabetes.

Authors:  Xiaotian Lin; Emma E Hamilton-Williams; Daniel B Rainbow; Kara M Hunter; Yang D Dai; Jocelyn Cheung; Laurence B Peterson; Linda S Wicker; Linda A Sherman
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

4.  IL-Y, a synthetic member of the IL-12 cytokine family, suppresses the development of type 1 diabetes in NOD mice.

Authors:  Rafael R Flores; Eun Kim; Liqiao Zhou; Chenjie Yang; Jing Zhao; Andrea Gambotto; Paul D Robbins
Journal:  Eur J Immunol       Date:  2015-09-01       Impact factor: 5.532

5.  Chronic follicular bronchiolitis requires antigen-specific regulatory T cell control to prevent fatal disease progression.

Authors:  Erica G Schmitt; Dipica Haribhai; Jonathan C Jeschke; Dominic O Co; Jennifer Ziegelbauer; Ke Yan; Yoichiro Iwakura; Manoj K Mishra; Pippa Simpson; Nita H Salzman; Calvin B Williams
Journal:  J Immunol       Date:  2013-10-25       Impact factor: 5.422

6.  Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production.

Authors:  Chang-Qing Xia; Ruihua Peng; Anna V Chernatynskaya; Lihui Yuan; Carolyn Carter; John Valentine; Eric Sobel; Mark A Atkinson; Michael J Clare-Salzler
Journal:  J Immunol       Date:  2014-06-27       Impact factor: 5.422

7.  Reduced interleukin-2 responsiveness impairs the ability of Treg cells to compete for IL-2 in nonobese diabetic mice.

Authors:  Cini R James; Irina Buckle; Franziska Muscate; Masayuki Otsuka; Mari Nakao; Jack Sh Oon; Raymond J Steptoe; Ranjeny Thomas; Emma E Hamilton-Williams
Journal:  Immunol Cell Biol       Date:  2016-01-14       Impact factor: 5.126

8.  Association of TLR5 sequence variants and mRNA level with cytokine transcription in pigs.

Authors:  X Yang; E Murani; S Ponsuksili; K Wimmers
Journal:  Immunogenetics       Date:  2012-11-07       Impact factor: 2.846

9.  Cellular mechanisms of restored β-cell tolerance mediated by protective alleles of Idd3 and Idd5.

Authors:  Emma E Hamilton-Williams; Jocelyn Cheung; Daniel B Rainbow; Kara M Hunter; Linda S Wicker; Linda A Sherman
Journal:  Diabetes       Date:  2011-11-21       Impact factor: 9.461

10.  Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement.

Authors:  Agata Kosmaczewska; Jerzy Swierkot; Lidia Ciszak; Aleksandra Szteblich; Agnieszka Chrobak; Lidia Karabon; Anna Partyka; Jacek Szechinski; Piotr Wiland; Irena Frydecka
Journal:  Rheumatol Int       Date:  2013-11-13       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.